CARTESIAN THERAPEUTICS INC (RNAC) Fundamental Analysis & Valuation

NASDAQ:RNAC • US8162123025

Current stock price

5.98 USD
-0.2 (-3.24%)
At close:
5.98 USD
0 (0%)
After Hours:

This RNAC fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. RNAC Profitability Analysis

1.1 Basic Checks

  • In the past year RNAC has reported negative net income.
  • RNAC had a negative operating cash flow in the past year.
  • In the past 5 years RNAC reported 4 times negative net income.
  • In the past 5 years RNAC always reported negative operating cash flow.
RNAC Yearly Net Income VS EBIT VS OCF VS FCFRNAC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -50M -100M -150M -200M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -44.85%, RNAC is in line with its industry, outperforming 50.48% of the companies in the same industry.
Industry RankSector Rank
ROA -44.85%
ROE N/A
ROIC N/A
ROA(3y)-44.59%
ROA(5y)-25.7%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
RNAC Yearly ROA, ROE, ROICRNAC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500 -500 1K

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for RNAC so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RNAC Yearly Profit, Operating, Gross MarginsRNAC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -10K -20K -30K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. RNAC Health Analysis

2.1 Basic Checks

  • RNAC does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, RNAC has more shares outstanding
  • RNAC has more shares outstanding than it did 5 years ago.
  • RNAC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
RNAC Yearly Shares OutstandingRNAC Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M 25M
RNAC Yearly Total Debt VS Total AssetsRNAC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M

2.2 Solvency

  • Based on the Altman-Z score of -4.15, we must say that RNAC is in the distress zone and has some risk of bankruptcy.
  • The Altman-Z score of RNAC (-4.15) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -4.15
ROIC/WACCN/A
WACC9.19%
RNAC Yearly LT Debt VS Equity VS FCFRNAC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M -50M -100M

2.3 Liquidity

  • A Current Ratio of 8.65 indicates that RNAC has no problem at all paying its short term obligations.
  • Looking at the Current ratio, with a value of 8.65, RNAC is in the better half of the industry, outperforming 74.27% of the companies in the same industry.
  • A Quick Ratio of 8.65 indicates that RNAC has no problem at all paying its short term obligations.
  • RNAC has a Quick ratio of 8.65. This is in the better half of the industry: RNAC outperforms 74.27% of its industry peers.
Industry RankSector Rank
Current Ratio 8.65
Quick Ratio 8.65
RNAC Yearly Current Assets VS Current LiabilitesRNAC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. RNAC Growth Analysis

3.1 Past

  • RNAC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 56.08%, which is quite impressive.
  • Looking at the last year, RNAC shows a very negative growth in Revenue. The Revenue has decreased by -92.96% in the last year.
  • The Revenue for RNAC have been decreasing by -29.96% on average. This is quite bad
EPS 1Y (TTM)56.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-505.08%
Revenue 1Y (TTM)-92.96%
Revenue growth 3Y-70.66%
Revenue growth 5Y-29.96%
Sales Q2Q%1129.87%

3.2 Future

  • The Earnings Per Share is expected to grow by 8.26% on average over the next years. This is quite good.
  • RNAC is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 156.44% yearly.
EPS Next Y35.32%
EPS Next 2Y14.87%
EPS Next 3Y11.82%
EPS Next 5Y8.26%
Revenue Next Year-79.69%
Revenue Next 2Y-54.93%
Revenue Next 3Y136.38%
Revenue Next 5Y156.44%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
RNAC Yearly Revenue VS EstimatesRNAC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 200M 400M 600M 800M
RNAC Yearly EPS VS EstimatesRNAC Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 -20 -40 -60 -80 -100

More info and screens

Find the best growth stocksShow best growing peers

0

4. RNAC Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for RNAC. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RNAC. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RNAC Price Earnings VS Forward Price EarningsRNAC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RNAC Per share dataRNAC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6 -8 -10

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y14.87%
EPS Next 3Y11.82%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. RNAC Dividend Analysis

5.1 Amount

  • No dividends for RNAC!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

RNAC Fundamentals: All Metrics, Ratios and Statistics

CARTESIAN THERAPEUTICS INC

NASDAQ:RNAC (4/10/2026, 8:00:01 PM)

After market: 5.98 0 (0%)

5.98

-0.2 (-3.24%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-09
Earnings (Next)05-07
Inst Owners28.06%
Inst Owner Change0.02%
Ins Owners39.9%
Ins Owner Change2.37%
Market Cap158.53M
Revenue(TTM)2.80M
Net Income(TTM)-132.93M
Analysts82.67
Price Target36.28 (506.69%)
Short Float %19.81%
Short Ratio11.22
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-185.12%
Min EPS beat(2)-310.13%
Max EPS beat(2)-60.11%
EPS beat(4)2
Avg EPS beat(4)-51.05%
Min EPS beat(4)-310.13%
Max EPS beat(4)160.52%
EPS beat(8)4
Avg EPS beat(8)-139.31%
EPS beat(12)5
Avg EPS beat(12)-104.56%
EPS beat(16)8
Avg EPS beat(16)-85.94%
Revenue beat(2)2
Avg Revenue beat(2)481.35%
Min Revenue beat(2)81.99%
Max Revenue beat(2)880.7%
Revenue beat(4)3
Avg Revenue beat(4)233.98%
Min Revenue beat(4)-64.04%
Max Revenue beat(4)880.7%
Revenue beat(8)5
Avg Revenue beat(8)301.25%
Revenue beat(12)6
Avg Revenue beat(12)191.21%
Revenue beat(16)9
Avg Revenue beat(16)165.59%
PT rev (1m)0%
PT rev (3m)0.81%
EPS NQ rev (1m)-1.53%
EPS NQ rev (3m)-3.52%
EPS NY rev (1m)3.52%
EPS NY rev (3m)3.52%
Revenue NQ rev (1m)-17.69%
Revenue NQ rev (3m)-28.9%
Revenue NY rev (1m)-32.12%
Revenue NY rev (3m)-32.12%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 56.68
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-5.13
EYN/A
EPS(NY)-3.32
Fwd EYN/A
FCF(TTM)-2.99
FCFYN/A
OCF(TTM)-2.79
OCFYN/A
SpS0.11
BVpS-4.76
TBVpS-10.12
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -44.85%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-44.59%
ROA(5y)-25.7%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 184.32%
Cap/Sales 195%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.65
Quick Ratio 8.65
Altman-Z -4.15
F-Score2
WACC9.19%
ROIC/WACCN/A
Cap/Depr(3y)332.92%
Cap/Depr(5y)235.75%
Cap/Sales(3y)73.05%
Cap/Sales(5y)44.3%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)56.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-505.08%
EPS Next Y35.32%
EPS Next 2Y14.87%
EPS Next 3Y11.82%
EPS Next 5Y8.26%
Revenue 1Y (TTM)-92.96%
Revenue growth 3Y-70.66%
Revenue growth 5Y-29.96%
Sales Q2Q%1129.87%
Revenue Next Year-79.69%
Revenue Next 2Y-54.93%
Revenue Next 3Y136.38%
Revenue Next 5Y156.44%
EBIT growth 1Y-138.74%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3Y-27.1%
EBIT Next 5Y10.05%
FCF growth 1Y-142.3%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-212.33%
OCF growth 3YN/A
OCF growth 5YN/A

CARTESIAN THERAPEUTICS INC / RNAC Fundamental Analysis FAQ

What is the ChartMill fundamental rating of CARTESIAN THERAPEUTICS INC (RNAC) stock?

ChartMill assigns a fundamental rating of 2 / 10 to RNAC.


Can you provide the valuation status for CARTESIAN THERAPEUTICS INC?

ChartMill assigns a valuation rating of 0 / 10 to CARTESIAN THERAPEUTICS INC (RNAC). This can be considered as Overvalued.


Can you provide the profitability details for CARTESIAN THERAPEUTICS INC?

CARTESIAN THERAPEUTICS INC (RNAC) has a profitability rating of 0 / 10.


What is the expected EPS growth for CARTESIAN THERAPEUTICS INC (RNAC) stock?

The Earnings per Share (EPS) of CARTESIAN THERAPEUTICS INC (RNAC) is expected to grow by 35.32% in the next year.